{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:47:43Z","timestamp":1791107263059,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1995,9,1]],"date-time":"1995-09-01T00:00:00Z","timestamp":809913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1995,9,1]],"date-time":"1995-09-01T00:00:00Z","timestamp":809913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1995,9]]},"DOI":"10.1007\/bf00873806","type":"journal-article","created":{"date-parts":[[2005,1,7]],"date-time":"2005-01-07T20:03:48Z","timestamp":1105128228000},"page":"235-240","source":"Crossref","is-referenced-by-count":29,"title":["Phase II study of topotecan in metastatic hormone-refractory prostate cancer"],"prefix":"10.1007","volume":"13","author":[{"given":"Gary R.","family":"Hudes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kosierowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry E.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Ozols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia A.","family":"McAleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J.","family":"Giantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF00873806_CR1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1200\/JCO.1985.3.6.827","volume":"3","author":"MA Eisenberger","year":"1985","unstructured":"Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827\u2013841, 1985","journal-title":"J Clin Oncol"},{"key":"BF00873806_CR2","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1073\/pnas.73.10.3488","volume":"73","author":"J Champoux","year":"1976","unstructured":"Champoux J: Evidence for an intermediate with a singlestrand break in the reaction catalyzed by the DNA untwisting enzyme. Proc Natl Acad Sci USA 73:3488\u20133491, 1976","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF00873806_CR3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0022-2836(78)90238-3","volume":"118","author":"J Champoux","year":"1978","unstructured":"Champoux J: Mechanism of the reaction catalyzed by the DNA untwisting enzyme: Attachment of the enzyme to the 3\u2032-terminus of the nicked DNA. J Mol Biol 118:441\u2013446, 1978","journal-title":"J Mol Biol"},{"key":"BF00873806_CR4","doi-asserted-by":"crossref","first-page":"14873","DOI":"10.1016\/S0021-9258(17)38654-4","volume":"260","author":"Y-H Hsiang","year":"1985","unstructured":"Hsiang Y-H, Hertzberg R, Hect S, Lius LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873\u201314878, 1985","journal-title":"J Biol Chem"},{"key":"BF00873806_CR5","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1093\/jnci\/84.23.1816","volume":"84","author":"HA Burris III","year":"1992","unstructured":"Burris HA III, Hanauske A, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG, Von Hoff DD: Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony forming units in vitro. J Natl Can Inst 84:1816\u20131820, 1992","journal-title":"J Natl Can Inst"},{"key":"BF00873806_CR6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev.bi.54.070185.003313","volume":"54","author":"J Wang","year":"1985","unstructured":"Wang J: DNA topoisomerases. Annual Rev of Biochem 54:665\u2013697, 1985","journal-title":"Annual Rev of Biochem"},{"key":"BF00873806_CR7","unstructured":"Topotecan (SK&F 104864-A) Investigator Brochure. June 1994"},{"key":"BF00873806_CR8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.1992.10.4.647","volume":"10","author":"EK Rowinsky","year":"1992","unstructured":"Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH, Donehower RC: Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10:647\u2013656, 1992","journal-title":"J Clin Oncol"},{"key":"BF00873806_CR9","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1200\/JCO.1993.11.8.1566","volume":"11","author":"HI Scher","year":"1993","unstructured":"Scher HI, Kelly WK: Flutamide withdrawal syndrome: Its impact on clinical trials in hormone refractory prostate cancer. J Clin Oncol 11:1566\u20131572, 1993","journal-title":"J Clin Oncol"},{"key":"BF00873806_CR10","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/1097-0142(19870901)60:5<1151::AID-CNCR2820600538>3.0.CO;2-G","volume":"60","author":"B Fishman","year":"1987","unstructured":"Fishman B, Pasternak S, Wallenstein SL, Houde R, Holland JC, Foley KM: The Memorial Pain Assessment Card: A valid instrument for the evaluation of cancer pain. Cancer 60:1151\u20131158, 1987","journal-title":"Cancer"},{"key":"BF00873806_CR11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1200\/JCO.1989.7.5.590","volume":"7","author":"I Tannock","year":"1989","unstructured":"Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W: Treatment of metastatic prostatic cancer with low-dose prednisone. Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590\u2013597, 1989","journal-title":"J Clin Oncol"},{"key":"BF00873806_CR12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.1992.10.6.881","volume":"10","author":"C Myers","year":"1992","unstructured":"Myers C, Cooper M, Stein C, LaRocca R, Walther MM, Weiss G, Choyke P, Dawson N, Steinberg S, Uhrich MM, Cassidy J, Kohler DR, Trexel J, Lineham WM: Suramin: A novel growth factor antagonist with activity in hormone refractory, metastatic prostate cancer. J Clin Oncol 10:881\u2013889, 1992","journal-title":"J Clin Oncol"},{"key":"BF00873806_CR13","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1200\/JCO.1992.10.11.1754","volume":"10","author":"GR Hudes","year":"1992","unstructured":"Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin S, Watts P, Speicher L, Tew K, Comis R: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10:1754\u20131761, 1992","journal-title":"J Clin Oncol"},{"key":"BF00873806_CR14","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1200\/JCO.1994.12.10.2005","volume":"12","author":"KJ Pienta","year":"1994","unstructured":"Pienta KJ, Redman B, Husain M, Cumings G, Esper PS, Appel C, Flaherty LE: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005\u20132012, 1994","journal-title":"J Clin Oncol"},{"key":"BF00873806_CR15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1200\/JCO.1994.12.4.683","volume":"12","author":"A Sella","year":"1994","unstructured":"Sella A, Kilbourn R, Amato R, Buic C, Zukiwski AA, Ellerhorst J, Logothetis CJ: Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12: 683\u2013688, 1994","journal-title":"J Clin Oncol"},{"key":"BF00873806_CR16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.1993.11.4.607","volume":"11","author":"WK Kelly","year":"1993","unstructured":"Kelly WK, Scher HI, Mazumdar M, Valmis V, Schwartz M, Fossa S: Prostate-specific antigen as a measure of disease outcome in metastatic hormone refractory prostate cancer. J Clin Oncol 11:607\u2013615, 1993","journal-title":"J Clin Oncol"},{"key":"BF00873806_CR17","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/jnci\/85.18.1499","volume":"85","author":"L Saltz","year":"1993","unstructured":"Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, Yao T, Tao T, Trochanowski B, Wright P, Barbasa K, Toomesi F, Kelson D: Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 85:1499\u20131507, 1993","journal-title":"J Natl Cancer Inst"},{"key":"BF00873806_CR18","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/jnci\/86.11.836","volume":"86","author":"A Tanizawa","year":"1994","unstructured":"Tanizawa A, Fujimori A, Fujimori Y, Pommier Y: Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86:836\u2013842, 1994","journal-title":"J Natl Cancer Inst"},{"key":"BF00873806_CR19","first-page":"1793","volume":"47","author":"MR Mattern","year":"1987","unstructured":"Mattern MR, Mong SM, Bartus HF, Mirabell CK, Crooke ST, Johnson RK: Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured 1210 cells. Cancer Res 47:1793\u20131798, 1987","journal-title":"Cancer Res"},{"key":"BF00873806_CR20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/jnci\/85.4.271","volume":"85","author":"WJ Slichenmeyer","year":"1993","unstructured":"Slichenmeyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH: The current status of camptothecin analogs as antitumor agents. J Natl Cancer Inst 85:271\u2013291, 1993","journal-title":"J Natl Cancer Inst"},{"key":"BF00873806_CR21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00685553","volume":"31","author":"PJ Houghton","year":"1992","unstructured":"Houghton PJ, Cheshire PJ, Meyers L, Stewart CFR, Synold TW, Houghton JA: Evaluation of 9-Dimethylaminomethyl-10-hydroxycamptothecin (Topotecan) against xenografts derived from adult and childhood tumors. Cancer Chemother Pharmacol 31:229\u2013239, 1992","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF00873806_CR22","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1126\/science.2555920","volume":"246","author":"BC Giovanella","year":"1984","unstructured":"Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M: DNA topoisomerase-I targeted chemotherapy of human colon cancer in Xenografts. Science 246:1046\u20131048, 1984","journal-title":"Science"},{"key":"BF00873806_CR23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1200\/JCO.1994.12.3.553","volume":"12","author":"H Hochster","year":"1994","unstructured":"Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ, Blum RH: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and welltolerated regimen. J Clin Oncol 12:553\u2013559, 1994","journal-title":"J Clin Oncol"},{"key":"BF00873806_CR24","first-page":"132","volume":"13","author":"GJ Creemers","year":"1994","unstructured":"Creemers GJ, Schellens JH, Beijnen JH, Planting AS, Rosing H, de Boer-Dennert M, van der Burg ME, Loos WJ, McDonald M, Stoter G, Verweij J: Bioavailability of oral topotecan, a new topoisomerase I inhibitor. Proceedings of ASCO 13:132, 1994","journal-title":"Proceedings of ASCO"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00873806.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00873806\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00873806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00873806.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T17:47:24Z","timestamp":1678556844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00873806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,9]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1995,9]]}},"alternative-id":["BF00873806"],"URL":"https:\/\/doi.org\/10.1007\/bf00873806","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,9]]}}}